Small molecule compounds targeting the p53 pathway: are we finally making progress?
Open Access
- 23 April 2014
- journal article
- research article
- Published by Springer Nature in Apoptosis
- Vol. 19 (7) , 1055-1068
Abstract
Loss of function of p53, either through mutations in the gene or through mutations to other members of the pathway that inactivate wild-type p53, remains a critically important aspect of human cancer development. As such, p53 remains the most commonly mutated gene in human cancer. For these reasons, pharmacologic activation of the p53 pathway has been a highly sought after, yet unachieved goal in developmental therapeutics. Recently progress has been made not only in the discovery of small molecules that target wild-type and mutant p53, but also in the initiation and completion of the first in-human clinical trials for several of these drugs. Here, we review the current literature of drugs that target wild-type and mutant p53 with a focus on small-molecule type compounds. We discuss common means of drug discovery and group them according to their common mechanisms of action. Lastly, we review the current status of the various drugs in the development process and identify newer areas of p53 tumor biology that may prove therapeutically useful.Keywords
This publication has 118 references indexed in Scilit:
- Metabolic Regulation by p53 Family MembersCell Metabolism, 2013
- TIGAR Is Required for Efficient Intestinal Regeneration and TumorigenesisDevelopmental Cell, 2013
- Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and SenescenceCell, 2012
- Allele-Specific p53 Mutant ReactivationCancer Cell, 2012
- Adjuvant treatment of GIST: patient selection and treatment strategiesNature Reviews Clinical Oncology, 2012
- Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenograftsCancer Letters, 2011
- Cancer Cell Metabolism: Warburg and BeyondCell, 2008
- p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR SignalingCell, 2008
- p53 Activation: A Case against SirCancer Cell, 2008
- Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 ActivatorCancer Cell, 2008